

## Special Issue

# Diagnosis, Pathogenesis, and Treatment of Inflammatory Bowel Disease

### Message from the Guest Editor

The pathogenesis of Inflammatory Bowel Disease (IBD) is complex and multifactorial, involving genetic, environmental, immune, and microbial factors. Future research is increasingly focused on understanding the interactions among these elements, with a specific emphasis on the gut microbiome and immune system. Studies have shown that IBD patients often exhibit dysbiosis, or an imbalance in the gut microbiota, which could trigger or exacerbate inflammation. Future research aims to map specific microbial signatures associated with IBD and understand their functional implications. With techniques like shotgun metagenomics and single-cell RNA sequencing, scientists are beginning to characterize individual microbial species and their roles in inflammation. Future treatment strategies will likely focus on precision medicine, where therapies are tailored to individual patient profiles, including their genetic background, microbiome composition, and immune responses. This Special Issue tries to provide an incentive approach for the available and future direction of IBD in terms of diagnosis, pathogenesis and therapies.

### Guest Editor

Dr. Bogdan Silviu Ungureanu

Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania

### Deadline for manuscript submissions

closed (28 February 2025)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/221438](https://mdpi.com/si/221438)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).